

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

EMT6

RRID:CVCL_1923

Type: Cell Line

Proper Citation

CLS Cat# 305159, RRID:CVCL_1923

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1923

Proper Citation: CLS Cat# 305159, RRID:CVCL_1923

Description: Cell line EMT6 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Malignant neoplasms of the mouse mammary gland

Defining Citation: [PMID:4647494](#), [PMID:31220119](#)

Comments: Characteristics: Established from the transplantable mammary tumour KHJJ.

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: EMT6

Synonyms: EMT-6, Experimental Mammary Tumour-6

Cross References: BTO:BTO_0003329, CLO:CLO_0002926, ATCC:CRL-2755, BioGRID_ORCS_Cell_line:1262, BioSample:SAMN11397651, ChEMBL-Cells:ChEMBL3307584, ChEMBL-Targets:ChEMBL614294, CLS:305159, NCI-DTP:EMT-6, PubChem_Cell_line:CVCL_1923, Wikidata:Q54832294

ID: CVCL_1923

Vendor: CLS

Catalog Number: 305159

Record Creation Time: 20220923T070658+0000

Record Last Update: 20260905T183007+0000

Ratings and Alerts

No rating or validation information has been found for EMT6.

No alerts have been found for EMT6.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 265 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Quan H, et al. (2026) Targeting the Vim-PGI2 Pathway Enhances CD8+ T Cell-Mediated Antitumor Immunity in Breast Cancer. Human mutation, 2026, 8880918.

Hou L, et al. (2026) C-type lectin domain family 5 member A-mediated activation of macrophages via a bispecific antibody enhances anti-HER2 therapy. Journal for immunotherapy of cancer, 14(4).

Deo A, et al. (2026) PD-1 Blockade-Induced DKK1 Expression by CD8+ T Cells Promotes Blood-Brain Barrier Permeabilization. Cancer discovery, 16(5), 976.

Wang X, et al. (2026) Targeting KDM3B Elicits Anti-tumor Immunity by Alleviating SHP1-mediated STING Suppression in Triple-Negative Breast Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e75846.

Jia L, et al. (2026) EFO2 promotes triple-negative breast cancer progression and reduces CD8+ T cell-mediated killing by acetylating USF1 to enhance SLC2A1-mediated glycolysis. Biochemical pharmacology, 253(Pt 1), 118260.

Zhang J, et al. (2026) Micro-Organ Chip Deciphers Tumor-Derived G-CSF as Remote Commander of Lung Pre-Metastatic Niche via VEGFA-KDR Cascade. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(7), e18584.

Lin W, et al. (2026) FAM135B Deficiency Inhibits Cytotoxic T-cell Activity in Triple-Negative Breast Cancer by Blocking the IFI16-Dependent STING Pathway. Cancer immunology research, 14(2), 335.

Gruber DR, et al. (2026) Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models. Molecular cancer therapeutics, 25(3), 457.

Yamaguchi A, et al. (2026) Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody-drug conjugates. *Antibody therapeutics*, 9(2), 127.

Nagaraj CK, et al. (2026) Microfluidic Nano-Assembly of Red-Blood-Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles. *Advanced healthcare materials*, e04351.

Domagala J, et al. (2025) Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin. *Cancer research*, 85(13), 2448.

Zhou TH, et al. (2025) Overexpression of RUNX2 promotes breast cancer multi-organ metastasis through stabilizing c-Myc. *Cell death & disease*, 16(1), 696.

Zhou X, et al. (2025) Potentiating anti-tumor immunity by re-engaging immune synapse molecules. *Cell reports. Medicine*, 6(3), 101975.

Mei W, et al. (2025) A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor. *Cell*, 188(2), 371.

Saini M, et al. (2025) StealTHY: An immunogen-free CRISPR platform to expose concealed metastasis regulators in immunocompetent models. *Cell*, 188(26), 7591.

Liu Y, et al. (2025) Dual ferroptosis induction in N2-TANs and TNBC cells via FTH1 targeting: A therapeutic strategy for triple-negative breast cancer. *Cell reports. Medicine*, 6(1), 101915.

Gu C, et al. (2025) An innovative engineered IL-10 monomer strengthens T cell-mediated anti-tumor responses through anti-PD-1 cis-delivery. *Cell reports. Medicine*, 102515.

Schwarz E, et al. (2025) Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer. *Cancer immunology research*, 13(4), 560.

Cui Q, et al. (2025) MIF-ACKR3 causes irreversible fat loss by impairing adipogenesis in cancer cachexia. *Cell metabolism*, 37(4), 954.

Taylor D, et al. (2025) Non-orthosteric inhibition of enolase 1 impedes growth of triple-negative breast cancer. *Cell reports. Medicine*, 6(11), 102451.